JNJ241108P85000
- 0.01
- 0.000.00%
Johnson & Johnson Newsroom
Bitcoin Gets Closer to $100k Than Ever | Wall Street Today
Sector Update: Health Care Stocks Edge Lower Wednesday Afternoon
Johnson & Johnson Sues US Government Over Rebate Model in Drug Discount Program
Bitcoin Breaks Above $90k, Market Flat Wednesday | Live Stock
Texas Instruments and Other Overlooked Dividend Aristocrat Stocks -- Barrons.com
Disease activity improved by over 70%. johnson & johnson (JNJ.US) potential blockbuster monoclonal antibody recognized as a breakthrough therapy.
Johnson & Johnson (JNJ.US) announced recently that the US FDA has granted Breakthrough Therapy Designation (BTD) to its investigational antibody therapy nipocalimab targeting the neonatal Fc receptor (FcRn), for the treatment of adult patients with moderate to severe primary Sjögren's syndrome.
J&J Sues HHS Over 340B Hospital Drug-discount Program
J&J Sues U.S. Over Hospital Drug-Discounting Program -- WSJ
Tuesday Market Finally Slows Down, Takes a Post Veterans Day Breather | Live Stock
3M, UnitedHealth Share Losses Lead Dow's 115-Point Drop
Express News | Johnson & Johnson Medtech Receives Ide Approval for Ottava™ Robotic Surgical System
Johnson & Johnson Today Announces That The U.S. FDA Has Granted Nipocalimab Breakthrough Therapy Designation For The Treatment Of Adults Living With Moderate-To-Severe Sjögren's Disease, A Debilitating And Chronic Autoantibody Disease With High...
Express News | Nipocalimab Is the First and Only Investigational Therapy Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Adults Living With Moderate-to-Severe Sjögren's Disease
Market Opens to Fresh Highs | Live Stock
Express News | Stand up to Cancer Collaborates With Johnson & Johnson to Explore Targeted Therapies for Rare Disease Linked to Blood Cancers
STAND UP TO CANCER COLLABORATES WITH JOHNSON & JOHNSON TO EXPLORE TARGETED THERAPIES FOR RARE DISEASE LINKED TO BLOOD CANCERS
Johnson & Johnson's (NYSE:JNJ) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
With Johnson & Johnson (NYSE:JNJ) It Looks Like You'll Get What You Pay For
Investors Elect to Accelerate Market on Election Week | Weekly Buzz
Friday Market Finished with Records | Wall Street Today